Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $31.00 at The Goldman Sachs Group

Viridian Therapeutics (NASDAQ:VRDN) had its price objective lowered by The Goldman Sachs Group from $36.00 to $31.00 in a research report released on Tuesday morning,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

Several other research firms also recently weighed in on VRDN. Needham & Company LLC decreased their target price on Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. UBS Group began coverage on Viridian Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 target price on the stock. Evercore restated an “outperform” rating and issued a $44.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, January 20th. HC Wainwright decreased their target price on Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Finally, Royal Bank Of Canada decreased their price target on shares of Viridian Therapeutics from $42.00 to $30.00 and set an “outperform” rating on the stock in a research note on Tuesday. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Viridian Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

Viridian Therapeutics Stock Performance

VRDN opened at $13.96 on Tuesday. The company has a quick ratio of 12.65, a current ratio of 12.65 and a debt-to-equity ratio of 0.08. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -4.24 and a beta of 1.16. Viridian Therapeutics has a 52-week low of $9.90 and a 52-week high of $34.29. The firm’s fifty day simple moving average is $27.58 and its two-hundred day simple moving average is $27.82.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.18). The company had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $15.75 million. Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. Equities analysts anticipate that Viridian Therapeutics will post -4.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Viridian Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC purchased a new position in Viridian Therapeutics during the fourth quarter worth approximately $46,680,000. Seven Fleet Capital Management LP purchased a new position in Viridian Therapeutics during the fourth quarter worth approximately $456,000. Virtu Financial LLC purchased a new position in Viridian Therapeutics during the fourth quarter worth approximately $531,000. Invesco Ltd. lifted its position in Viridian Therapeutics by 127.1% during the fourth quarter. Invesco Ltd. now owns 183,468 shares of the company’s stock worth $5,710,000 after buying an additional 102,676 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Viridian Therapeutics during the fourth quarter worth approximately $1,464,000.

Viridian Therapeutics News Roundup

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Goldman Sachs cut its price target from $36 to $31 but kept a “buy” rating, implying substantial upside versus the current price and signaling continued analyst conviction. Benzinga
• Positive Sentiment: Royal Bank of Canada lowered its target from $42 to $30 but retained an “outperform” rating, again indicating analysts still see long‑term value despite near‑term headwinds. Benzinga
• Neutral Sentiment: Coverage roundup: a Globe & Mail piece groups Viridian with other healthcare names and summarizes recent analyst commentary — useful context but no new company‑specific catalyst. Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Bristol-Myers Squibb (BMY)
• Negative Sentiment: Competitive clinical risk: Amgen reported positive Phase 3 results for a thyroid eye disease program (TEPEZZA OBI trial reported a 77% proptosis response), which investors view as direct competition to Viridian’s lead program and has been cited as a main reason for recent selling pressure. Why Is Viridian Therapeutics Stock Sinking Monday?
• Negative Sentiment: Press coverage highlights the Amgen link as the driver of the drop, increasing investor concern about VRDN’s addressable market and near‑term commercial prospects. Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.
• Negative Sentiment: Sentiment/flow signal: unusual options activity — ~7,501 put contracts purchased (a large multiple of typical volume) — indicating hedging or speculative bearish bets that can accelerate downside moves in volatile sessions.
• Negative Sentiment: MSN and other outlets note VRDN has fallen to 9‑month lows amid the Amgen developments, underscoring the short‑term negative narrative investors are reacting to. VRDN stock falls to 9-month lows – what’s the Amgen connection?

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.